POPULARITY
Allyson with a Y. Ocean with two Ls. And zero chill when it comes to changing the face of cancer care. Dr. Allyson Ocean has been quietly—loudly—at the center of every major cancer breakthrough, nonprofit board, and science-backed gut punch you didn't know you needed to hear. In this episode, she joins me in-studio for a conversation two decades in the making. We talk twin life, genetics, mitochondrial disease, and why she skipped the Doublemint Twins commercial but still ended up as one of the most recognizable forces in oncology. We cover her nonprofit hits, from Michael's Mission to Let's Win Pancreatic Cancer to launching the American Jewish Medical Association—yes, that's a thing now. We get personal about compassion in medicine, burnout, bad food science, and microplastics in your blood. She also drops the kind of wisdom only someone with her résumé and sarcasm can. It's raw. It's real. It's the kind of conversation we should've had 20 years ago—but better late than never.RELATED LINKS:– Dr. Allyson Ocean on LinkedIn– Let's Win Pancreatic Cancer– NovoCure Leadership Page– Michael's Mission– American Jewish Medical Association– The POLG Foundation– Cancer Buddy App (Bone Marrow and Cancer Foundation)– Dr. Ocean at OncLiveFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Tune in as Glenn Hunzinger, PwC's Health Industries Leader, and Phil Scalfani, PwC's Pharmaceutical and Life Sciences Consulting Leader, discuss the Trump administration's executive order on Most Favored Nation (MFN) drug pricing and its far-reaching implications across the healthcare ecosystem. They break down what MFN pricing could mean for pharmaceutical companies, payers, PBMs, and the broader drug supply chain, and share perspectives on how organizations can navigate the uncertainty ahead. Discussion Highlights: The MFN executive order is a bold attempt to lower U.S. drug prices by benchmarking them against the lowest prices paid in other high-income countriesPharma companies may be forced to rethink global pricing strategies, balancing U.S. price cuts with potential increases or market exits abroadA proposed shift to direct-to-consumer drug access could disrupt traditional roles for pharmacies, distributors, and pharmacy benefit managers (PBMs)Companies are preparing for significant uncertainty by reassessing deals, modeling financial impacts, and closely monitoring upcoming rulemaking and potential legal developmentsSpeakers:Glenn Hunzinger, Health Industries Leader, PwCPhilip Sclafani, Partner, Pharma & Life Sciences, PwCLinked materials:Most Favored Nation prescription drug pricing Executive OrderFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.What makes this conversation essential listening:96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubatorsThree critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraintsThe future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusionThis isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian GiehringConnect with Tom Valentin:LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091bWebsite: www.csem.ch/enEmail: thomas.valentin@csem.chNext step:Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/callDevelop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/Support the show
What happens when cutting-edge science meets compassion? In this episode of Sounds of Science, host Mary Parker sits down with two pioneers reshaping the future of research: Elizabeth Nunamaker, Executive Director of Global Animal Welfare and Training at Charles River, and Dr. Megan LaFollette, Executive Director of the 3Rs Collaborative. From digital biomarkers to environmental health monitoring, they reveal how innovation and collaboration are redefining what's possible in animal welfare — and raising the bar for ethical, high-quality research. Tune in to explore the tools, strategies, and bold ideas driving meaningful change across the scientific community.Show NotesAdvancing Alternatives | Charles RiverEvolving Animal Welfare: Science, Ethics, and Innovation | Sounds of Science Can You Practice High-quality Science and 3Rs? | Eureka BlogAnimals in Research | Charles RiverResearch Models & Services | Charles River
We love to hear from our listeners. Send us a message. On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders. Internal drug development efforts at atai are focused on short-duration psychedelics that can work within existing healthcare infrastructure, with the potential to transform the treatment of mental health disorders. Rao also talks about atai's hub and spoke model for investing in other psychedelic companies, what MAPS/Lykos Therapeutics got wrong in the run-up to FDA's review of Lykos's MDMA candidate for PTSD, and whether psychedelic therapies need the "trip" to catalyze network disruption and neuroplasticity in the brain. This episode of the Business of Biotech is brought to you by Avantor. For more information, visit avantorsciences.comAccess this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Managing editor Anna Townshend spoke with two team members at BioMADE, which is one of nine different Manufacturing Innovation Institutes started by the Department of Defense. This particular group is focused on building the U.S. bioindustrial economy. There are many companies and scientists doing great work using chemical waste products to create new products that we often lack a domestic supply chain for, and the organization is also focused on commercializing and scaling the technology needed to do this work and the workforce to support the industry. Jill Zullo, executive vice president and chief operating officer at BioMADE, has a long career supporting sustainable products and focused on new bioindustrial markets. Most recently, she worked at Cargill, as interim president & CEO of NatureWorks, a Cargill joint venture focused on biomanufacturing development to replace fossil fuel-based materials. Tim Dobbs, data architect for BioMADE's data science team, is a chemical engineer with a degree from the University of Connectivity and a master's degree in Life Sciences. At BioMADE, he designs, models and deploys data models to BioMADE's member organizations. He and the technology team at BioMADE provide the unified computational infrastructure for bioproduction-centered collaboration across industry, academia and government.
Sponsored by Invivyd, Inc.Nobody wants to hear about COVID-19 anymore. Especially not cancer patients. But if you've got a suppressed immune system thanks to chemo, radiation, stem cell transplants—or any of the other alphabet soup in your chart—then no, it's not over. It never was. While everyone else is getting sweaty at music festivals, you're still dodging a virus that could knock you flat.In this episode, Matthew Zachary and Matt Toresco say the quiet part out loud: many immunocompromised people may not even know they have options beyond vaccines. Why? Because the system doesn't bother to tell them. So we're doing it instead. We teamed up with Invivyd to help get the word out about tools other than vaccines that can help prevent COVID-19. We break down the why, the what, and the WTF of COVID-19 risk for cancer patients and why every oncologist should be talking about this.No fear-mongering. No sugarcoating. Just two guys with mics who've been through it and want to make sure you don't get blindsided. It's fast, funny, and furious—with actual facts. You've got more power than you think. Time to use it.RELATED LINKSExpand Their OptionsInvivydMatt Toresco on LinkedInOut of Patients podcastFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this special episode of Trending Health, Mindy McGrath and Karen Baldry explore how recent changes across the U.S. federal health agencies and policies from the new administration are impacting the life sciences and biotech industry compounding with other pressures like the IRA, tariffs, and budget constraints. From launch delays at the FDA to supply chain strain and evolving patient access challenges, Mindy and Karen provide strategic considerations for commercial leaders as they navigate these shifts and uncertainties. To learn more about how we can help your team with scenario planning and navigating these strategic decisions, reach out to . Check out our recent insights for more information: U.S. Federal Health Agency Layoffs Pose Strategic Risk and Disruption to Life Sciences & The Case for Strategic Transformation: An Executive Conversation with Vynamic's Leaders Podcast Tags: healthcare, life sciences, public health, life sciences trends, healthcare strategy, health innovation Panel – Mindy McGrath, Karen Baldry Research & Production – Mindy McGrath, Karen Baldry, Everly Petruzzelli Recording & Editing – Mike Liberto, Rachel Skonecki
This is the daily Tech and Business Report. Today, KCBS Radio anchor Eric Thomas spoke with Bloomberg's Robert Langreth. The cost of cancer drugs has been skyrocketing, but now questions are being raised about just how beneficial they are. A recent analysis in JAMA Oncology found that a drop in cancer deaths between 1975 and 2020 was due mostly to improved screening and preventative health measure, and not new treatments.
Today's guest is Daniel Ferrante, AI Leader in R&D and Data Strategy at Deloitte. Daniel joins Emerj CEO and Head of Research Daniel Faggella on today's show to delve into the intersection of AI, data strategy, and research and development across industries such as agriculture, life sciences, and materials science. Ferrante breaks down the core challenges organizations face in harnessing data to unlock AI's potential and drive efficiencies in R&D processes. Ferrante also emphasizes the importance of contextualizing data through a multimodal framework — Deloitte's Atlas — to bridge gaps between disparate datasets and ontologies. He outlines how AI models, including large language models (LLMs), can be leveraged to label and map complex data landscapes. This episode is sponsored by Deloitte. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on the ‘AI in Business' podcast!
Beim Schweizer Verband für Life Sciences freut man sich über die Nachricht, dass das globale Onkolgie-Unternehmen "BeOne" seinen Firmensitz nach Basel verlegt. Dies zeige die Attraktivität des Pharma-Standorts Basel. Ausserdem: · Schweizerische Rheinhäfen kaufen Schifffahrts-Simulator · Basler Regierung rechnet weiterhin mit leichtem Minus fürs 2025
atai Life Sciences CEO and co-founder Dr Srinivas Rao talked with Proactive's Stephen Gunnion about the company's clinical development progress in 2025, highlighting multiple upcoming trial readouts. He discussed new data from Beckley Psytech's Phase 2a trial of BPL-003, a psychedelic compound being evaluated in patients already taking SSRIs. Rao confirmed the trial showed “very good safety and tolerability and very robust efficacy,” with results from a broader Phase 2b trial expected mid-year. Rao also detailed progress on RL-007, a candidate targeting cognitive impairment in schizophrenia, which is also in Phase 2b. He added that VLS-01 (Illumina study) and EMP-01 for social anxiety disorder will report data early in 2026. EMP-01 is being trialed in a six-week study with two administrations, using the Liebowitz Social Anxiety Scale as the primary endpoint. “We wanted to go after a different indication — there's really no one focused on social anxiety disorder currently with a psychedelic compound,” Rao said, underlining the novelty of their approach. Rao further noted investor interest in broader industry readouts, including those from Compass, in which atai remains a shareholder. For more updates from atai Life Sciences and other biotech innovators, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and turn on notifications for future content. #ataiLifeSciences #PsychedelicTherapy #ClinicalTrials #MentalHealthInnovation #BPL003 #EMP01 #SocialAnxietyDisorder #BiotechNews #PharmaUpdates #RL007 #VLS01 #FDAApprovalPath #ProactiveInvestors #Biotech2025 #SSRI
EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to outcomesrocket.com Organizations must recognize that AI risk management is a shared responsibility across the entire organization, not solely confined to cybersecurity, legal, or compliance teams. In this episode, Michael Crowthers, Managing Director of Life Sciences Digital Quality & Compliance, and Chris Knackstedt, Managing Director of Cyber and Strategic Risk Practice at Deloitte & Touche, discuss the major challenges to AI adoption, highlighting governance, ethics, and compliance as top concerns. They emphasize the importance of integrating AI governance into existing risk management frameworks and navigating regulatory uncertainty, talent gaps, and ethical usage policies. The conversation also explores risks posed by AI agents, such as runaway behavior, misaligned learning, and context untraceability, stressing the need for human oversight and robust behavioral evaluations. Looking ahead, Michael anticipates a rise in governance tech to manage evolving AI risks, while Chris encourages organizations to build on their cybersecurity foundation and maintain momentum in AI strategy. Tune in and learn how to navigate the complex landscape of AI risk management and secure adoption! Resources: Connect and follow Mike Crowthers on LinkedIn. Connect and follow Chris Knackstedt on LinkedIn. Learn more about Deloitte on their LinkedIn and website. Subscribe to The Current, Deloitte Cyber's quick-read series. Read our life sciences and health care industry insights. Visit the Deloitte AI Institute™ website. Explore The State of Generative AI in the enterprise 2024 year-end report.
Host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests.This week his guests are Joe Morrow, IT Director, Technology Services at OSF Healthcare, and Sandra Colner, Global GM/Sr. Director of Healthcare and Life Sciences at Dell Technologies. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
Host Gil Bashe welcomes Dan Sheeran, Amazon Web Services' General Manager for Healthcare and Life Sciences – in a far-reaching conversation about technology's impact on health. The discussion explores how cloud computing, data analytics, and artificial intelligence (AI) are accelerating innovation from drug discovery to patient care. Dan Sheeran shares insights from his front-line experience as a digital health entrepreneur and AWS leader, emphasizing a mission-driven approach to improving global health outcomes. Key themes include speeding up the development of new therapies, expanding telehealth access, strengthening healthcare security, and applying Amazon's customer-centric ethos to healthcare. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
On this episode, we are joined by Rey Altamirano -- Director of Life Sciences and Healthcare at Peacock Construction.Rey's success story began working for his father's construction company, and he initially decided construction wasn't for him. Then, he found a professor in college who led him to fall back in love with construction. Fast forward to today, Rey is a prolific Project Leader focused on Healthcare and Life Sciences, who has also done an incredible job winning work for Peacock Construction.In this episode, we discuss:• What Rey enjoys about being a part of the team at Peacock• How his experience has differed going from larger GCs to a smaller GC• How his experience at the “big boys” helped him improve the systems and processes at Peacock• How he has helped add a significant amount of backlog work to Peacock through relationships and business developmentAnd much more…If you're looking to hear a story about a construction leader who fell out of love and back into love with construction, how Rey has significantly increased the backlog for their team during the pandemic, or how a Healthcare and Life Sciences construction leader has taken their experience at larger GC's to impact a smaller GC -- you're in for a gem with this episode!
What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Matters Microbial #91: You Are What Your Genes Feed Your Microbiome May 16, 2025 Today, Dr. Emily Davenport, Assistant Professor in the Department of Biology and Huck Institutes of the Life Sciences at Penn State University, joins the #QualityQuorum to tell us about the research her team does, studying how our own genes impact our microbiomes. Host: Mark O. Martin Guest: Emily Davenport Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A description of GWAS (“Genome Wide Association Study”). Here is an introductory video about the concept. An explainer on organoids. An essay about the diversity of the host microbiome (i.e. is there a “healthy” microbiome?). An article of the work of Dr. Sarkis Mazamian on how individual host genes and bacterial genes can impact the microbiome. A nice write up for Dr. Mazamian's work showing how host genes and bacterial genes can work together…or not. An oldish video of how the infant microbiome develops over time by Dr. Rob Knight's research group. An article on the same topic from Dr. Ruth Ley. An essay on the mucosal microbiota, rather than the fecal microbiome. An interesting member of the human microbiome, Akkermansia that might be related to obesity. Another interesting member of the human microbiome, Bifidobacterium, which appears to be associated with host lactose metabolism. Yes, there is a Giant Microbes plush toy. An overview of the impact of host genetics on the microbiome by Dr. Davenport. A definition of heritability. An overview of the Hutterites and how their study has advanced genetics. An explainer of the power of twin studies in genetics. A fascinating article about ancient dental plaque microbiome by Dr. Davenport and others. Dr. Davenport's faculty website. Dr. Davenport's research group website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com
In this episode of Investor Connect, we welcome Alan Foreman, the CEO of Be Secure, who discusses the transformative journey of his company in the realm of heart health. Alan shares that he founded Be Secure nine years ago after a lengthy career in Accenture's Life Sciences division. Currently, the company is on a $12 million growth raise to commercialize its breakthrough heart health technology, which received FDA clearance recently. Be Secure focuses on making preventive rather than reactive heart health solutions, leveraging their powerful, device-agnostic software that offers high accuracy ECG readings in consumer and medical devices alike, such as the latest versions of the Whoop and Fitbit devices. Alan elaborates on how the recent challenges faced by Philips, a significant player in heart monitoring technology, present both a testament to the need for better solutions and an opportunity for Be Secure to make a substantial impact on the market. Alan details the company's innovative use of cybersecurity experts and detailed signal processing to develop technology that bridges consumer wellness and medical-grade ECG technology. He highlights how Be Secure's cloud-based and on-device solutions offer transformative accuracy and efficiency in heart monitoring, even earning the interest of major insurers like Blue Cross Blue Shield. The conversation turns to the scalability and swift deployment of Be Secure's solutions in medical environments, emphasizing how their data quality can accelerate and improve diagnosis in cardiologists' workflows. Alan stresses the importance of their upcoming scale-up and commercial focus, particularly in filling the funding gap to expedite the deployment of their remarkable technology in the healthcare space. We also learn about Be Secure's financials and investment strategy, which involves contributions from venture capital and venture debt providers. Alan emphasizes ongoing discussions with top medical companies and the anticipated rapid revenue growth fueled by the latest FDA clearance. The episode wraps with Alan addressing some practical questions about scaling, design timelines, and the lifecycle of deals with their partners, giving a comprehensive view of Be Secure's promising future. For more updates and opportunities to engage with Alan and Be Secure, stay tuned to Investor Connect. Thank you for joining us for the Startup Funding Espresso where we help startups and investors connect for funding. Let's go startup something today. _______________________________________________________ For more episodes from Investor Connect, please visit the site at: Check out our other podcasts here: For Investors check out: For Startups check out: For eGuides check out: For upcoming Events, check out For Feedback please contact info@tencapital.group Please , share, and leave a review. Music courtesy of .
Clay is an American inventor and serial entrepreneur who holds more than 250 patents worldwide and is the Founder and Chairman of Ember, a global consumer electronics and life sciences brand best known for the Ember Mug, Ember Baby Bottle, and Ember Cube, all three of which independently have been named TIME Magazine's Best Inventions of the year. Ember was also recently named one of TIME Magazine's 100 Most Influential Companies in the world. Top 3 Value Bombs 1. Founder's gut can be a very powerful thing. 2. The team is the No. 1 factor. Putting together an incredible powerhouse team is key. 3. Inch by inch life's a cinch. Buy the yard, life's hard. Take one bite at a time and keep chugging it forward. Check out Clay's patented technology temperature control mugs and other products - Ember Sponsors The Speaker Lab - Want to learn how to get booked and paid to speak. Go to EOFire.com/speaker to grab your spot for our LIVE training on May 28th, and learn how to get booked and paid to speak. ThriveTime Show - Become the next success story, schedule a free consultation and request tickets to join Football Star, Tim Tebow and President Trump's Son, Eric Trump at Clay Clark's next business conference today at - ThrivetimeShow.com/eofire.
Channing Hamlet, Managing Director and Co-Founder of Objective, Investment Banking & Valuation, joins Amanda Ma, CEO & Founder of Innovate Marketing Group, to discuss the rising "flight to quality" in the event industry. Learn how consolidation is transforming the landscape — and how event businesses can adapt, scale, and thrive in a shifting market.About the guest:Channing Hamlet is the Managing Director and Co-Founder of Objective, Investment Banking & Valuation. He leads the firm's Business Services & Life Sciences Practice. With over 25 years of experience in investment banking and business valuation, Channing brings deep expertise and strategic insight to Objective's clients. His recent notable transactions include the sale of 360 Destination Management to H.I.G. Capital and Supreme to Trinity Hunt Partners. An active member of the Los Angeles advisor community, Channing has served on the boards of the Exit Planning Institute, ACG LA, and EO LA. He is also passionate about philanthropy, particularly through his involvement with Reality Changers. Prior to joining Objective, Mr. Hamlet served as a Managing Director of Cabrillo Advisors, where he was instrumental in both leading their M&A execution and growing the valuation practice from inception into a national entity serving more than 700 clients in five years. Previously, he served as a Director at Vistage; Principal at LLR Partners, a $260 million private-equity firm; and member of Legg Mason's Investment Banking group. He has a Master's Degree in Operations Research and a Bachelor of Science in Mechanical Engineering from Cornell University. He holds FINRA Series 7, 63 and 79 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.Connect with Channing Hamlet on LinkedIn hereRead about the sale of 360 Destination Management Group hereDownload the The Introspective CEO's Guide to Selling a Business, a high-level workbook covering key considerations for those contemplating a sale here.Objective, Investment Banking & Valuation is a leading firm serving middle market companies across key industries including Business Services, Consumer, Healthcare Tech, Life Sciences, Manufacturing, and Technology. We offer M&A advisory through our investment banking group and a full suite of valuation services for tax, financial reporting, and strategic planning. Since 2006, our team has completed over 500 M&A deals and thousands of valuations. Learn more at objectiveibv.comThis podcast episode is for informational purposes only and does not constitute investment, legal, or tax advice. Securities offered through BA Securities, LLC, Member FINRA, SIPC. Objective and BA Securities, LLC are separate, unaffiliated entities.EventUp is brought to you by Innovate Marketing Group. An award-winning Corporate Event and Experiential Marketing Agency based in Los Angeles, California. Creating Nationwide Immersive Event Experiences to help brands connect with people. To learn more, click here.Follow us!Find us on LinkedIn, EventUp Podcast LinkedIn , and Instagram
Solving the “Undruggable” Disease Problem with Goldilocks MoleculesIn this episode, Christian Schafmeister, Founder and President of Third Law Molecular, reveals a new class of therapeutics designed to target what most consider “undruggable” diseases—conditions like Alzheimer's, certain cancers, and rare genetic disorders.Christian explains the science behind spiroligomers—modular, mid-sized molecules that act like molecular LEGOs, offering the perfect balance between small molecules and biologics. Learn how his team created a library of 4.5 billion molecules and what makes these structures uniquely suited to bind difficult protein targets, including disordered proteins and intracellular surfaces.We also talk about the Goldilocks Zone of drug design, how Third Law's chemistry was born out of academic and defense-backed research, and why the future of drug discovery may lie in designing therapeutics that are just right.
Today's guest is Brice Challamel, Head of AI products and Innovation at Moderna. With experience working across five continents, he brings a global perspective to driving AI adoption, innovation management, and measurable results in life sciences. Brice joins Emerj Managing Editor Matthew DeMello to explore how Moderna is embedding AI into both its tools and corporate culture to scale collaboration, accelerate product development, and improve regulatory outcomes. He breaks down how AI is augmenting human creativity, enhancing team decision-making, and supporting patient engagement efforts, while keeping human insight at the center of AI strategy. Brice also shares lessons from other industries to shed light on what's ahead for AI in regulated sectors like life sciences, where the technology has the potential to improve operational efficiency, vaccine adoption, and broader public health outcomes. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast! This episode is sponsored by MSTRO. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.
In this episode, host Sandy Vance sits down with Dr. Will Morris, Chief Medical Officer at Ambience Healthcare, to explore how AI is transforming the healthcare industry. From enhancing clinical documentation to improving patient care and supporting back-office operations, Ambience is creating intelligent solutions tailored for the entire healthcare ecosystem.Dr. Morris shares insights on how AI, when used as an assistive—not replacement—tool, can help alleviate clinician burnout and empower medical professionals to focus on what matters most: delivering compassionate, human-centered care. Whether you're a healthcare leader, clinician, or innovator, this episode offers practical insights into leveraging AI to drive real value across your organization.In this episode, they talk about:● AI should assist—not replace—medical professionals, enabling them to focus on essential human-centered care.● AI is not a commodity; it must address critical pain points to drive real value.● Ambient AI must work for all specialties, not just primary care. AI models must be tuned to the nuances of each specialty.● Reducing burnout is just the start. When coding-aware, Ambient AI greatly improves clinical documentation integrity and provides coding support at the point-of-care, capturing other lost revenue.● Always measure results, outputs, and processes when implementing new healthcare technologies.● The effectiveness of any system depends on the quality and consistency of clinical documentation.● Successful AI adoption requires a unified, enterprise-wide strategy.A Little About Will:Will Morris, MD, MBA, is board-certified in Internal Medicine and is a health technology leader, currently serving as Chief Medical Officer at Ambience Healthcare. In this role, he drives the company's vision for clinical AI, collaborating with leading health systems to transform clinician workflows and improve patient care. Before joining Ambience, Dr. Morris was Chief Medical Information Officer at Google Cloud Healthcare and Life Sciences, contributing to cutting-edge healthcare innovations. He previously held leadership roles at Cleveland Clinic, including Chief Innovation Officer and Associate Chief Information Officer, overseeing clinical IT systems and health IT advancements.
In this episode, Stephanie Major, a senior at Iowa State University, outlines a research project that aimed to better understand how bacon becomes discolored under varying types of retail lights. With Major as co-leader of the research team, the study involved treating cured bacon with natural antioxidants and then packaging the product in aerobic (overwrap) and anaerobic (vacuum packed) containers. Major and Dr. Terry Hauser, associate director at Iowa State's College of Agriculture and Life Sciences, explain the results of the study, which found that the type of packaging was more effective than an antioxidant treatment alone in preventing photo-oxidation in bacon in storage or on retail shelves.
Written by Robert Thomas and Sarah Batchelor & narrated by Gayle Grew. This article explores key design principles for creating life sciences spaces that enhance collaboration among scientists, researchers, and professionals.
In this powerful episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Katrina Rogers, a 25-year life sciences veteran, biotech equity advocate, and founder of Evergreen Bioscience Innovation and Katrina Rogers Consulting. Katrina shares her compelling journey from Pfizer to pioneering innovation ecosystems and mentoring underrepresented biotech founders. They unpack the role of board governance, the funding gap for female founders, and how "showing your science" is critical for regulatory success. Katrina also warns of dangerous gaps in understanding between regulators and innovators and why we must protect our basic science infrastructure. If you've ever dreamed of launching a breakthrough therapy, leading a biotech, or making your idea count, this episode is for you.00:00 Episode Preview & BioTalk Unzipped Introduction03:09 Katrina's Charity Highlight: 2nd Harvest (link below)04:04 Defining Moment in Life Science05:35 Launching a Consultancy: Overcoming Fears07:12 Leadership Lessons09:30 The Importance of Board Composition13:08 NEW NEWS: The Case for Female Founders18:04 Knowledge Gaps Between Founders and Regulators20:23 The Impact of Regulatory Changes21:32 The Direct Attack on Basic Scientific Infrastructure25:57 Understanding Market Needs29:36 The Role of Founders in Leadership and Navigating Leadership Challenges34:00 The Most Common Mistake by Biotech Founders & What To Do35:27 Katrina's Scope & Delivering Unpleasant News36:51 NEW NEWS: Understanding Tariffs and Drug Pricing42:23 Empowering Big Ideas45:26 Overcoming Systemic Barriers47:24 Advice to My Younger Self49:38 Proposing Changes to FDA Innovation Pathways54:54 The Future of Innovation in BiotechnologyKatrina Rogershttps://www.linkedin.com/in/katrinarogers/ https://krogersconsulting.com/ Katrina's Favorite Charity: 2nd Harvest (Food Bank) - https://2-harvest.org/ Dr. Chad Briscoehttps://www.linkedin.com/in/chadbriscoe/ Celerion - https://www.celerion.com/ Gregory Austinhttps://www.linkedin.com/in/gregoryaustin1/ Celerion - https://www.celerion.com/ NEW NEWSBiotech a Bright Spot for Female Founders Amid DEI Pullback, https://www.biospace.com/business/biotech-a-bright-spot-for-female-founders-amid-dei-pullback?utm_source=chatgpt.com Trump signals shift in drug import tariff policy
Comment on this episode by going to KDramaChat.comToday, we'll be discussing Episode 9 of When Life Gives You Tangerines, the hit K Drama on Netflix starring IU as Oh Ae-sun, Park Bo-gum as Yang Gwan-sik as young adults, and Moon So-ri as Oh Ae-sun and Park Hae-joon as Yang Gwan-sik as older adults. We discuss:The song featured during the recap: "Midnight Walk" by IU, a sweet ballad of longing that reflects Geum Myeong's and Ae Sun's emotional states of mind.How this episode subtly shifts focus to Geum Myeong as the central figure, possibly revealing the show as her coming-of-age story.The Baeksang Awards wins in 2025, including Best Drama, Best Supporting Actress, Best Supporting Actor, and Best Screenplay for When Life Gives You Tangerines!Our shoutouts to Lori and Seven Seas, who shared their love for the podcast and personal stories that echo themes in the show.The Yang family's move to a cramped apartment, and Ae-sun's determination to bring her cherished mother-of-pearl armoire to their new apartment.Eun Myeong's emotional journey—his bitterness, rebellion through hairstyles, and quiet gestures of love toward Ae Sun, like placing tennis balls under his mom's chair.Geum Myeong's return from Japan and the lack of exploration of her time abroad, which disappointed both of us.The awkward and growing connection between Geum Myeong and Park Chung Seop, who keep running into each other, and who the staff at the theater want to push closer together.The breakdown of Geum Myeong and Yeong-beom's relationship, and how Park Chung Seop might be quietly emerging as a romantic lead. Does Geum Myeong marry him in the end?The Romeo and Juliet parallel between Eun Myeong and Bu Hyeon-suk, son and daughter of two families that have been intertwined forever but are enemies!The beautiful poem “Natasha, the White Donkey and Me” by Baek Seok, read by Geum Myeong from Chung Seop's notebook.A spotlight on Lee Jun-young (Jun)—his career in K-pop and K Drama, including his rap and acting performances. We love him as Park Yeong Beom in this drama!How we're excited to watch the film "The Match" on Netflix, starring Lee Byung-hun and Yoo Ah-in. This movie is about an epic match Go between a mentor and mentee! ReferencesBloomberg Innovation Index in 2021Healthcare and Life Sciences as a Strategic Focus for South KoreaNatasha, the White Donkey and Me by Baek Seok‘Ghost' Director Lauds the Korean Sense of ResponsibilityCircle of Love by Lee Jun youngAmazing rap by Jun young of U KissKal-guksu - WikipediaJjolmyeon - Wikipedia
Recorded at SCBio's 2025 annual conference, hosts Heather and Matthew welcome keynote speaker John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), the world's leading advocacy group for the life sciences industry. In this inspiring episode, John shares his personal journey in biotech, including his fight to improve his children's lives after a rare disease diagnosis that inspired a major film, and offers insight into what lies ahead for the industry. Tune in to hear how his story and lifelong work are transforming lives and advancing science.
Why do most recruitment companies stall at 10 to 20 people, while others scale to 100+ across continents? In this episode, you'll hear directly from someone who's done it. STR Group is a family of specialist recruitment brands focused on STEM sectors. As co-founder, Clive Hutchings has spent over two decades growing the business to more than 120 staff across the UK, Europe, and the US—all while staying profitable, adaptable, and values-driven. In this interview, Clive breaks down what it really takes to build a multi-brand, international recruitment group, the leadership philosophy behind STR's culture, and the gritty truths behind scaling a business beyond yourself. Episode Outline and Highlights [3:05] The early days: how Clive started in recruitment and his story of practicing his pitch in front of a mirror in the office. [11:37] The operational and leadership shifts needed to grow from 10 to 100+ employees [19:19] Why many recruitment founders plateau—and how to avoid it [21:09] Discussion on the best approach to train a new recruiter. [27:33] The value of having a support network around you. [32:50] What is the formula for knowing when to make your next hire? [40:00] Impact of AI: “Sales people being more sustainable, resourcing people less so.” [41:45] Clive reveals their tech stack and how AI impacts their current operations. [45:00] The relevance of cold calling in the age of AI. [52:00] Big differences between hiring in the US and the UK. [1:02:10] Learnings on expanding globally. [1:07:00] Culture and mantra that work. Leadership That Scales One of the biggest takeaways from this conversation is the importance of evolving your role as a founder. Clive credits much of STR's growth to the fact that he didn't try to do everything himself. Instead, he and his co-founder took on complementary leadership roles, allowing each to focus on their strengths while building out a business that could scale beyond them. If you're stuck juggling billing, management, and strategy, this is your sign to rethink your leadership structure. Building a scalable firm means building scalable leadership, and that starts with letting go of being the bottleneck. He also elaborated on the following: 1. Multifaceted Leadership Structure 2. Team Composition and Talent Strategy 3. High Energy and Personal Drive 4. Resilience Through Early-Stage Challenges 5. Realistic Growth Mindset Clive's success as a leader came from building a balanced team, maintaining high personal energy, fostering a resilient and realistic culture, and adapting roles and structures to match the stage of the business. Decision Factors When to Make Your Next Hire With Clive's success in scaling his team globally, I wanted to pick his brains on his thought process when deciding to make a new hire. As a recruitment business owner, this is a critical decision to make, as doing it too slowly can impede your business's growth, while doing it too rapidly can lead to longer-term problems that cost more to fix. Clive shared the following decision factors: Strategic Forecasting & Business Planning - Hiring plans are based on quarterly forecasts developed by each brand's leadership. Critical Mass & Team Size Considerations - A certain headcount is needed to reach operational momentum, but hiring must be sustainable. Smaller teams (e.g.,
Today's guest is Marie Flanagan, Director of Product Management in Digital Projects and Solutions at IQVIA, who joins us to explore the overlooked intersection of AI and safety workflows in life sciences. As the industry experiences an explosion in the volume and diversity of data—from social media and call centers to audio and video files—Marie outlines the mounting challenges for pharmacovigilance and the opportunities AI is unlocking for healthcare and life sciences leaders. Marie discusses how advancements in voice-to-text transcription and automation are helping safety teams manage massive datasets, pinpoint potential risks, and reallocate human resources toward high-value activities like signaling and benefit-risk management. She also shares insights into where human expertise remains essential, particularly in interpreting complex clinical contexts that AI alone cannot fully capture. Want to share your AI adoption story with executive peers? Click emerj.com/expert2 for more information and to be a potential future guest on Emerj's flagship ‘AI in Business' podcast!
"You're not stuck—you're just scared to take up space."In this episode of The Counter Offer, host Susanna Gray is joined by her co-host for the season, recruiter-turned-career-coach Tiarna Mccormack. Tiarna brings sharp insight into the job search process, why women especially struggle to own their stories, and what it really takes to move your career forward. They dig into the unspoken power dynamics between recruiters and candidates, how burnout fuels bad decisions, and why quiet quitting might not be the answer you're looking for.If you've ever felt invisible in your career or doubted your next move, this episode will give you the mindset reset you didn't know you needed.Must-Hear Insights and Key MomentsFrom Recruiter to Coach – Tiarna shares her transition from the recruitment world to career coaching, explaining how personal burnout and professional misalignment led her to find deeper meaning in helping people unlock clarity and confidence.The Power of Owning Your Story – The conversation dives into why so many people—especially women—struggle to articulate their worth and how career coaching can help shift those narratives.Quiet Quitting: A Symptom, Not a Solution – Tiarna breaks down why quiet quitting is a red flag for deeper disengagement and how it can be an opportunity to reflect and pivot before you fully burn out.Recruiter Red Flags – Susanna and Tiarna expose what candidates often miss when dealing with recruiters and how to spot the signs that a role—or a recruiter—isn't aligned with your values.Job Search Mindset Reset – They unpack why desperation in a job search backfires and how reframing the process around curiosity and ownership leads to better long-term outcomes.Words of Wisdom: Standout Quotes from This Episode“When people come to me, they think the problem is their résumé—but it's really their relationship to their career.” – Tiarna Mccormack“You're not stuck—you're just scared to take up space.” – Tiarna Mccormack“Quiet quitting is a coping mechanism for something much deeper.” – Tiarna Mccormack“Owning your story is about reclaiming your career narrative before someone else writes it for you.” – Tiarna Mccormack“If a recruiter makes you feel small, that's a massive red flag.” – Tiarna Mccormack“Most of the time, people already know what they want—they just need permission to want it.” – Tiarna Mccormack“When you're desperate in a job search, you show up differently—and you attract the wrong opportunities.” – Susanna Gray“Your self-worth should not be tied to your job title.” – Tiarna Mccormack“We're not meant to stay in the same role for 5, 10, 15 years and feel nothing.” – Tiarna Mccormack“Clarity in your career isn't found in a spreadsheet—it's found in your story.” – Susanna GrayAbout Tiarna MccormackTiarna Mccormack is a recruitment professional with over 10 years of experience, specializing in connecting senior talent with recruitment agencies. She has held key roles, including Director, Associate Partner, and Regional Director, across sectors such as HR, Technology, Life Sciences, and Accountancy & Finance. Tiarna focuses on executive search, interim solutions, and talent acquisition while helping senior professionals achieve their career goals.Her approach centers on building strong relationships, emphasizing the importance of communication and trust in recruitment. Tiarna is also committed to coaching and mentoring, supporting individuals in unlocking their potential and advancing their careers.Outside of work, Tiarna enjoys traveling, yoga, and spending time with friends over a glass of wine. She believes in fostering meaningful connections and creating opportunities for others. For senior-level recruitment support or career advice, Tiarna is an experienced and trusted partner to collaborate with.Connect with Tiarna MccormackLinkedInFollow The Counter Offer:LinkedIn HostLinkedIn PodcastInstagramTiktok
Rackspace Technology leverages decades of experience and a cloud-first approach to help healthcare organizations optimize costs, drive transformation, and enhance security. In this episode, PV SubbaRao, Senior Vice President of Global Healthcare and Life Sciences at Rackspace Technology, shares how his organization partners with key healthcare sectors to drive innovation. He discusses Rackspace's evolution from early internet hosting to leading cloud solutions that optimize costs and enhance efficiency. PV highlights how the company supports EHR implementations, data center transformations, and security improvements, helping health systems achieve 18-25% savings. He also explores the future of healthcare technology, emphasizing AI, quantum computing, and extended reality as key drivers of personalized medicine and data-driven value. Join us and learn how Rackspace's specialized healthcare team can help your organization transform and scale for the future! Resources: Connect with and follow PV SubbaRao on LinkedIn. Learn more about Rackspace Technology on their LinkedIn and website.
三腳貓很榮幸邀請到擁有5000+粉絲的臉書粉專「實驗鼠的七分鐘廢文」的實驗鼠來跟大家分享自己從博士班開始在粉專分享生活和實驗室裡的大小事（鬼故事）的契機，想更認識實驗鼠「阿鼠姊姊」嗎？想知道粉專名稱是怎麼來的嗎？想聽更多粉專裡面沒有講到的鬼故事嗎？那就絕對不要錯過這一集！ 工作人員 內容製作：實驗鼠的七分鐘廢文、若晴、Angel 剪輯：若晴 後製：若晴 文案：若晴 封面：雯薇 上架：若晴 宣傳：Angel、雯薇 -- Hosting provided by SoundOn
Show Notes: Steven Chao, a US-born second-generation college student, shares his experiences growing up in South Carolina and feeling overwhelmed upon arriving at Harvard in 1988. He found solace in joining the Collegium Musicum, a classical musical singing group at Harvard, which helped him find his footing and connect with people from his class. From Biochem to Game Design to Consulting Steven majored in biochemistry, which expanded his social circle and helped him find happiness. Steven's parents were both PhDs and pushed him into the MD PhD program. However, he faced challenges in medical school and research, leading to questions about his path and the decision to pursue a career in computer gaming. Steven talks about his experience working in the sound and asset acquisition field at Activision in LA. He initially had a great time there but ultimately decided that it wasn't the long-term solution for him. He returned to his PhD program and he pinned his hopes on becoming a doctor. During the last half of the MD program, Steven realized that he didn't want to be a researcher or go into medicine. He found an opportunity to explore other careers beyond medicine or research through a sub-intern at McKinsey. The McKinsey Years Steven joined McKinsey full-time in 2001 and worked in the Boston office. The bulk of his work was in the payer and provider space, mainly health insurance and hospital systems. He spent about four and a half years at McKinsey, starting from scratch with no business background, which proved difficult. Steven's PhD focused on biology, not analytical skills, but rather gene genetic rearrangement and plasmids, and he felt lost at the beginning of McKinsey. At the same time, he also participated in the mini MBA program in Austria. Despite meeting great friends at McKinsey, his work was hit or miss. Steven talks about a few of the McKinsey projects he worked on and how a pharma project with Jeff Elton piqued his interest in returning to biopharma. He later worked with Kim Packard, who was his first and best mentor at McKinsey. Steven was late to promotion and advancement, and in 2004, when his wife became pregnant, he gave up his job and started considering what he would do next. Boutique Consulting, Life Sciences, and Biotech Companies In 2004, Steven joined a small consulting group at an investment bank called Leering Swan, which focused on life sciences and biotech companies. This was a better fit for Steven, who had always wanted to leverage his love for science. He joined the firm and was assigned to a project in Parkinson's disease. The experience was mind-blowing, as he interviewed world experts in this space. He was hooked within a week and found the career to be a good fit for him. The combination of his love for science and medicine, without needing to do research or have a career in clinical practice, was perfect, as he loved learning about different aspects of medicine, and the variety and diversity of the day-to-day work. Founding ClearView Steven left Leering Swan with two other people in 2008 to co-found ClearView. ClearView was born of the same concept as Leering Swan, but focused on life sciences, biotech, pharma, private equity clients, diagnostics companies, and strategic consulting. Steven's primary hat was recruiting, and he continued to love every second of doing so. ClearView Healthcare Partners is now a well-known, private consulting firm with several 100 employees. The company has a growing presence in London, India, San Francisco, New York, and Boston. Family Life and a Love of Musicals On the personal side, Steven has a family of four children, three girls and a boy. They also have two in college and two still in high school. The oldest is a sophomore at Harvard. Music has always been a significant part of their family. They have a love for Broadway musical theater, and they have spent a lot of time attending performances. Their youngest son is doing a local production of Hadestown in Wellesley, and their oldest is performing at the Agassi theater in a production of 9-5, the film with Dolly Parton, which has themes of female empowerment. Timestamps: 04:50: Transition to Medical School and Early Career Challenges 13:14: Joining McKinsey and Early Consulting Experience 23:20: Discovering a Passion for Biopharma Consulting 30:04: Founding ClearView Healthcare Partners 37:27: Personal Life and Family Featured Non-profit: Hi. This is Steve Chao, class of 1992. The featured nonprofit of this episode of The 92 report is the Merriemack Repertory Theater. My wife and I love live theater. The MRT is a fantastic organization that puts on plays and musicals every year, serving a wide catchment area in and around Lowell, Massachusetts. I was actually introduced to the MRT via a fellow class of 92 Carrie Suzawa, married named Michael. And you can learn more about the work of the MRT through the website, mrt.org. And for now, here is Will Bachman with this week's episode. To learn more about their work, visit: https:mrt.org.
The health tech fundraising environment shows promise. More deals are occurring alongside modest growth in total funding, suggesting a shift toward realistic valuations. In this episode, Julie Ebert, managing director of Healthcare and Life Sciences for Silicon Valley Bank, discusses the key findings from their annual Future of Health Tech report, highlighting the growth of AI adoption in healthcare as well as the increasing focus on specialty value-based care models. She noted a third of health tech companies that have raised money have an AI component, and half of the investment is in the administrative use of AI. Julie also explains that value-based care is moving from primary care to specialties due to these areas being complex and costly. Finally, she emphasizes that Silicon Valley Bank is playing a bold role in providing transparency to companies by offering working capital solutions and releasing reports that allow companies to have the knowledge to move forward. Tune in and learn about the current landscape of health tech investment and the future of value-based care! Resources: Connect with and follow Julie Ebert on LinkedIn. Follow Silicon Valley Bank on LinkedIn and visit their website. Read this year's SVB's Future of Healthtech report here.
In this episode of Manufacturing Hub, we welcome Amy Williams, Systems Architect at Skellig, for a deep dive into the world of life sciences manufacturing, a rarely explored but incredibly complex part of the industrial landscape.From her roots in biomolecular chemical engineering to her hands-on role in Operation Warp Speed, Amy walks us through what it's really like to build and validate manufacturing systems for pharmaceutical and biotechnology applications under FDA regulation.
Neha Sharma is a Product Manager at Grantek, she has 10+ years of experience in defining technology solutions to solve business/IT problems for manufacturers. Over the years, Neha has worked across various positions such as Software Developer, Module Lead, Techno-Functional Consultant and Manufacturing Engineer. Neha has worked for world class clients across the globe. Neha has experience in the automotive industry, packaging industry, agricultural industry, building materials, food & beverage and pharmaceuticals. The Industry 4.0 Podcast with Grantek delivers a look into the world of manufacturing, with a focus on stories and trends that lead to better solutions. Our guests will share tips and outcomes that will help improve your productivity. You will hear from leading providers of Industrial Control System hardware and software, Grantek experts and leaders at best-in-class industry associations that serve Life Sciences and Food & Beverage manufactures.
Inside INdiana Business Radio for the morning of May 1, 2025. Purdue launches a new institute in honor of a Hoosier life sciences icon. Plus, Ivy Tech Community College names its next president. Get the latest business news from throughout the state at InsideINdianaBusiness.com.
Why Startups Fail (Hint: It's Not the Innovation)In this episode, Carlo Odicino, CEO and Founder at One TEAM Partners, shares the real reasons why most early-stage life sciences companies struggle to survive—and it has nothing to do with bad science.Learn the hidden pitfalls of scaling too fast, confusing innovation with execution, and chasing too many priorities at once. Carlo offers practical strategies for building focus, setting boundaries, and creating a people-first culture that actually scales. You'll also learn why execution beats experimentation when commercial success is the goal—and how to stay aligned with investors without over-promising.This conversation is packed with actionable advice for startup leaders, biotech founders, and anyone facing the complexities of early-stage growth.
On this week's episode, host Sophia McLeod is joined by Danilo Branco (Associate Director, Risk Based Quality Management Lead, BeOne Medicines) and Amanda Coogan (Associate Director, Customer Experience, Remarque Systems) to discuss the value of centralized monitoring implementation by sharing case studies from today's clinical trials. They dive deeper into how centralized monitoring can help detect adverse events more quickly and identify underreporting, the benefits of holistically monitoring trial data using centralized monitoring, and how a targeted SDV/SDR sampling strategy can help organizations to conserve resources while maintaining quality and safety.
Quinn Dixie of Oklahoma talks with Viktor Devonne about military service, parenting, adoption, joining burlesque in one's 30s, traveling, plus the impending Burlesque Hall of Fame Weekender where she is to debut in Movers, Shakers, and Innovators. All this and and how to bump it with a trumpet accordingly, so grab yer brass. This chat was recorded on April 6, 2025. Give love to the folks… Quinn on IG: https://www.instagram.com/quinndixietheokie/ More Viktor: http://www.instagram.com/viktordevonne More WEBurlesque: http://www.instagram.com/weburlesque FOOTCLOTHES! Get 10% off your order with the code VIKTORDEVONNE at FOOTCLOTHES.COM
In this episode, Duane Mancini interviews Kelly Collier at LifeX on the dynamic life science startup ecosystem thriving in Pittsburgh. We explore the unique synergy between major academic institutions like the University of Pittsburgh and Carnegie Mellon University, and healthcare giants such as UPMC and Allegheny Health Network. Discover Kelly's entrepreneurial journey and learn how LifeX provides crucial support and programming for emerging life science companies. We also discuss the common pitfalls startups face and the specific advantages Pittsburgh offers to innovators. Tune in to understand the key ingredients fueling Pittsburgh's rise as a life science hub.Kelly Collier LinkedInLifeX WebsiteDuane Mancini LinkedInProject Medech WebsiteProject Medtech LinkedIn
Host Justin Barnes recorded live at HIMSS25 in Las Vegas. Stay tuned for the next few weeks to hear all his guests.This week his guests are Tony Nunes, Senior Manager, Healthcare & Life Sciences at AMD, and Leigh Burchell, Vice President, Policy & Public Affairs at Altera Digital Health. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
In this episode of The Digital Executive, host Brian Thomas welcomes Ed Marx, a seasoned healthcare leader whose journey began humbly as a clinical janitor at 16. Ed shares how his diverse experience—from combat medic to CIO of top institutions like Cleveland Clinic and NYC Health + Hospitals—shaped his leadership style rooted in humility and service. He discusses the importance of relationships, compelling vision, and speaking the customer's language when driving digital transformation in complex healthcare environments.Currently focused on his advisory practice and board work, Ed Marx also reflects on his time at Tech Mahindra Health and Life Sciences and other leading organizations. He offers compelling insights into the next wave of healthcare innovation—from voice-driven care to hyper-personalization and advanced virtual care. Tune in for a thought-provoking conversation packed with practical wisdom and forward-looking ideas for any digital health leader.
When Your Life Sciences Are on the Line: False Claims Act by Morrison & Foerster LLP (MoFo)
Disclaimer: This episode was recorded on April 11th, 2025, and reflects the information available at the time of recording. As we know, America is in motion here, and so subsequent updates may not be reflected in this discussion as things continue to evolve and change. Tune in as PwC specialists from across the health industry share their insights on how recent policy shifts under the Trump administration could shape healthcare in the years to come. In this episode, Glenn Hunzinger, Jenny Colapietro, and guests Kelly Griffin, Phil Sclafani, and Ruchita Kewalramani break down the potential implications of proposed government healthcare cuts, tariff policy and agency workforce reductions, along with the growing role of AI in the industry. They also discuss how pharma, medtech, payers and providers can stay ahead amidst the uncertainty. Discussion highlights:Proposed funding cuts to major government healthcare programs like Medicare, Medicaid, and NIH could significantly disrupt access, affordability, and service delivery across the healthcare landscape.Workforce reductions at federal agencies like the Food and Drug Administration (FDA), Centers for Disease Control and Prevention (CDC), and Health and Human Services (HHS) may slow drug approvals, diminish oversight, and impact public health standards.New and evolving tariff policies are creating cost pressures across pharmaceutical and medtech supply chains, with potential downstream impacts on pricing, R&D, and patient access.The rapid adoption of AI in healthcare is creating new opportunities across diagnostics, R&D, and operations, while also raising concerns around governance and data privacy.To stay ahead, industry leaders must assess risks, strengthen agility, and uncover opportunities to innovate in today's dynamic environment.Speakers:Kelly Griffin, Director, Health Policy Intelligence Institute, PwCRuchita Kewalramani, Partner, Health Services PwCPhil Sclafani, Partner, Pharma & Life Sciences, PwCGlenn Hunzinger, Partner, Health Industries Leader, PwCJenny Colapietro, Principal, Consulting Commercial Leader, PwCLinked materials:Health Policy and Intelligence InstituteFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
Tom welcomes back Peter Goodburn from WaveTrack International to discuss his analysis of the financial markets. Goodburn's focus is on Elliott Wave analysis and he believes that the current market environment can be understood as a binary relation to tariffs. If tariffs continue, stock markets will decline, and gold prices will rise. Conversely, if negotiations cool off, the stock market may recover, but gold prices may experience profit-taking sell-offs. Goodburn also shared his perspective on interest rates, suggesting that Treasury yields are heading lower due to the perception of increasing inflation risks. He believes this decrease in yields indicates that a US downturn is likely, although he did not specify a timeframe for when this may occur. The interview also touched upon copper prices, with Goodburn noting that China's position on strategic metals could impact their availability and pricing going forward. As the conversation concludes, Goodburn emphasized the importance of following price levels and wave patterns instead of being overly reliant on news flow to make trading decisions. Time Stamp References:0:00 - Introduction1:00 - Analysis of the Markets3:27 - S&P Charts & Sentiment10:37 - Nasdaq Outlook13:04 - Blow-Off Technicals17:42 - Global Capital Rotation24:54 - Global Market Surveys25:37 - Dr. Copper & Tariffs31:38 - China & Rare Earths34:26 - Gold's Strength & Inflows38:12 - Gold Pullback Coming?44:47 - US Dollar Thoughts48:30 - Jerome Powell & Rates51:13 - Weak Canadian Peso54:55 - Treasuries & Yield Spikes59:22 - Tariffs & Inflation1:04:50 - Crude Oil Prices1:09:06 - Wrap Up Guest Links:Twitter: https://twitter.com/ElliottWave_WTIWebsite: https://wavetrack.com Peter Goodburn is the founding partner of WaveTrack International. His trading experience spans back to the late 1970s working then in the commodities business for exchange members and their clients. In those earlier years of his career, he created the first OTC (over-the-counter) copper option product based upon the Comex (New York) contract around the mid-eighties, and in the same period, devised Opval, an option-evaluation software program that is currently used in many of the major market-making institutions of today. His fascination with price activity and how that related to the news flow within the markets captured his imagination early on. Peter's first annual diary of 1978 records his notes and remarks on how the interaction and relationship of fundamental news and price movement often contradicted themselves. Some years later, this was to ignite his interest in causal theory and naturally, the Elliott Wave Principle. He was first introduced to the Elliott Wave Principle in the mid-eighties listening to daily updates of financial commentary by Bob Beckman on LBC radio (London Broadcasting Company). This led him to the work of Frost/Prechter and their first re-publication of R.N.Elliott's (1871-1948) original treatise of 1938 (The Wave Principle) and 1946 (Nature's Law – The Secret of the Universe), entitled "the Elliott Wave Principle" (1978). Peter's a self-proclaimed purist of the Wave Principle but has developed a unique approach of geometric Ratio & Proportion that is instrumental in maintaining a dispassionate and objective view of the market. He has applied this analysis to every major asset class over the years, stocks, bonds, currencies & commodities, and promotes the importance of interdependency of the combined group. Peter has been a member of the U.K.'s Society of Technical Analysts (STA) for over twenty-five years and is a Certified Financial Technician recognized by the International Federation of Technical Analysts (IFTA). He has taught the Elliott Wave Principle to students at the London School of Economics as part of the STA's diploma program and is a member of the Foundation for the Study of Cycles and the Society for Chaos Theory in Psychology and Life Sciences.
Accommodation requests are evolving, and life sciences employers are witnessing a surge in diverse and creative requests. Chapters 00:00 The Rise of Accommodation Requests in Life Sciences 05:44 Navigating the Interactive Process 12:10 Challenges in Fast-Paced Startups 16:57 Establishing Effective Accommodation Processes
© 2020-2025 Ivy Podcast Discovery LLC
